Trial Profile
A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Jul 2021
Price :
$35
*
At a glance
- Drugs TAK 071 (Primary) ; Donepezil
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Takeda
- 08 Jul 2021 Results published in the British Journal of Clinical Pharmacology
- 27 Mar 2018 Status changed from recruiting to discontinued as data from cohort no longer needed due to indication change.
- 02 Aug 2017 Planned number of patients changed from 142 to 186.